Cutaneous T Cell Lymphomas: From Pathology to Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 74
Special Issue Editors
Interests: Hodgkin and non-Hodgkin lymphoma; cutaneous lymphoma; pre-clinical models and targeted therapy for mycosis fungoides and Sezary syndrome
Special Issue Information
Dear Colleagues,
Cutaneous T cell lymphomas (CTCL) are a rare subtype of non-Hodgkin lymphoma and a malignancy of skin-homing T cells. CTCL represents a heterogenous group of diseases that presents primarily in the skin at the time of diagnosis. Mycosis fungoides, the variants of mycosis fungoides, and Sezary syndrome (MF/SS) are the most common types, accounting for approximately 60% of all CTCLs. Early-stage mycosis fungoides may manifest as wide-spread, intensely pruritic skin lesions that significantly impact both quality of life and daily functioning. Advance-stage MF/SS can be life-threatening with a survival rate of 3.5 to 5.6 years. Due to its rarity, heterogeneous presentation, and clinical course, the clinical care of MF/SS presents unique challenges that are best addressed through a multidisciplinary approach.
In recent years, remarkable progress has been made in the field of CTCL. The revision of classification has contributed to a more precise diagnosis, prognosis, and treatment of CTCL. Employing state-of-the-art molecular and genetic techniques has provided insights into the potential genetic drivers and therapeutic targets. A deeper understanding of the functions of epigenetic modulation and tumor microenvironment has opened avenues for the discovery of novel therapies and the development of strategies to overcome drug resistance. Moreover, gaining insights into the mechanisms of action and treatment responses of novel agents, with the identification of prognostic biomarkers, is propelling us toward a more personalized therapeutic approach.
For this Special Issue of Cancers, we welcome original research and review articles that encompass the recent advances and address the future challenges in the diagnosis, biological insights, and treatment of CTCL.
Dr. Weiyun Z. Ai
Dr. Christiane Querfeld
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cutaneous T cell lymphoma
- mycosis fungoides and Sezary syndrome
- pathogenesis/biomarker discovery
- tumor microenvironment
- pre-clinical and clinical studies
- biological insights
